Back to All Events

Biocom September Breakfast Meeting

This has been a pretty good year for the biotech industry; this has been a spectacular year for the biotech industry in San Diego. In the second quarter of this year one San Diego biotech company went public and raised $50 M; another was acquired for $175 M; a third company was acquired for $650 M and, not to be outdone, a fourth local biotech was acquired for $707 M. This activity all occurred within a 3 month period. The panel for this event will have the leaders of the four afore mentioned companies.

Nothing is easy in the biotech world and each of these companies have had multiple obstacles to overcome and skeptics to convince--- so, before we pop the cork on the 2013 vintage, this group will discuss mistakes made, lessons learned and future paths to be followed. And who better to lead this discussion and probe the panel, than a San Diego-based venture capitalist who founded a company back in 2005 which had its own sweet exit this month-being acquired for $275 M? Please plan on attending this panel discussion; listening, learning and asking your own questions.

David Kabakoff/Executive Partner Sofinnova Ventures

Rich Heyman/CEO of Aragon Pharmaceuticals
Jeff Stein/President and CEO of Trius Therapeutics
Kleanthis Xanthopolous/President and CEO of Regulus Therapeutics


RSVP by Tuesday, September 24, 2013 12:00 p.m. 



 Hyatt Regency La Jolla

3777 La Jolla Village Drive 

San Diego, California 92122


Earlier Event: September 24
BioBriefing: Biotech for the Non-Scientist
Later Event: October 2
BIOCOM/BEDC Annual HR Conference 2013